MAPT and Alzheimer disease: Given our sample excluding individuals with a clinical diagnosis of AD, the substantial proportion of amyloid‐ and tau‐positive individuals indicates that plasma p‐tau217 is a useful biomarker for determining AD biological continuum independent of cognitive staging and can guide in screening, diagnosis, and prognosis of AD.